Clinical Trials · NCT01642732
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
- Phase
- Phase 1
- Recruitment status
- Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Enrollment
- 1
- Start date
- Oct 2012
- Locations
- 2 sites, United States
- Primary endpoint
- Number of Patients With Adverse Events on Oral Everolimus in Combination With Hormonal Ablation and External Beam Radiation